Overview

Droperidol on Prevention of Cannabis Hyperemesis Syndrome

Status:
Recruiting
Trial end date:
2023-01-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the efficacy of droperidol as a treatment of cannabinoid hyperemesis syndrome.
Phase:
Phase 3
Details
Lead Sponsor:
Mercy Health Ohio
Collaborator:
Lake Erie College of Osteopathic Medicine
Treatments:
Diphenhydramine
Droperidol
Promethazine